Urszula Adamska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Urszula Adamska has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Rafał Czajkowski
Nicolaus Copernicus Univ Torun, Fac Med Bydgoszcz, Chair Dermatol Sexually Transmitted Dis & Immunod, Torun, Poland
10 shared publicationsAgnieszka Białecka
Nicolaus Copernicus Univ Torun, Fac Med Bydgoszcz, Chair Dermatol Sexually Transmitted Dis & Immunod, Torun, Poland
8 shared publicationsKaja Męcińska-Jundziłł
Nicolaus Copernicus Univ Torun, Fac Med Bydgoszcz, Chair Dermatol Sexually Transmitted Dis & Immunod, Torun, Poland
7 shared publications- Piotr Adamski
Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
5 shared publications Adam Cichewicz
Chair of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Faculty of Medicine in Bydgoszczy, Copernicus University in Torun, Poland
3 shared publicationsAleksandra Grzanka
Clinic of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Faculty of Medicine in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
3 shared publications
Latest Publications
- Open Access
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 38 (2) , 343-345
Dermatomyositis associated with gastrointestinal malignancies – report of two cases and a literature review
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 38 (2) , 343-345
Open AccessDermatomyositis associated with gastrointestinal malignancies – report of two cases and a literature review
- 22 August 2018
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 19 (13) , 1415-1425
Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations
Introduction: Acute coronary syndromes (ACS) represent one of the most perilous presentations of ischemic heart disease. Temporal trends clearly demonstrate that ACS occur later and later in life. Elderly patients with ACS comprise a populous and growing group, with more than half of individuals presenting with myocardial infarction being 75 years or older. Nevertheless, geriatric patients are greatly underrepresented in the landmark ACS trials evaluating innovative pharmacological strategies. Areas covered: The authors critically summarize recently published research on contemporary and emerging antithrombotic therapy for the treatment of ACS in geriatric patients. Expert opinion: Elderly ACS patients are characterized by simultaneously increased risk of cardiovascular events and bleeding. Very few studies assessing the efficacy and safety of novel ACS pharmacotherapy in geriatric patients are currently available. Guidelines on the treatment of ACS are based on the overall results of major randomized clinical trials (RCTs), and data supporting the recommended therapy in elderly mainly derive from subanalyses of these RCTs. Properly designed and powered RCTs are necessary to properly evaluate the net effect of current and emerging pharmacotherapy in geriatric patients. Until such data are available, elderly ACS patients should receive treatment according to the general recommendations.
- 22 August 2018
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 19 (13) , 1415-1425
Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations
Introduction: Acute coronary syndromes (ACS) represent one of the most perilous presentations of ischemic heart disease. Temporal trends clearly demonstrate that ACS occur later and later in life. Elderly patients with ACS comprise a populous and growing group, with more than half of individuals presenting with myocardial infarction being 75 years or older. Nevertheless, geriatric patients are greatly underrepresented in the landmark ACS trials evaluating innovative pharmacological strategies. Areas covered: The authors critically summarize recently published research on contemporary and emerging antithrombotic therapy for the treatment of ACS in geriatric patients. Expert opinion: Elderly ACS patients are characterized by simultaneously increased risk of cardiovascular events and bleeding. Very few studies assessing the efficacy and safety of novel ACS pharmacotherapy in geriatric patients are currently available. Guidelines on the treatment of ACS are based on the overall results of major randomized clinical trials (RCTs), and data supporting the recommended therapy in elderly mainly derive from subanalyses of these RCTs. Properly designed and powered RCTs are necessary to properly evaluate the net effect of current and emerging pharmacotherapy in geriatric patients. Until such data are available, elderly ACS patients should receive treatment according to the general recommendations.
- Open Access
- 4 February 2018
- Published by Termedia Sp. z.o.o. in Polish Journal of Radiology
- Vol. 83, 63-67
Imaging in a rare case of neuroendocrine tumour with skin metastases
Purpose : Disseminated malignancies are a diagnostic and therapeutic challenge that is often encountered in radiology. Finding the primary tumour is crucial for planning proper surgical and oncological treatment. Computed tomography (CT) of the thorax and abdomen is typically the initial...
- 4 February 2018
- Published by Termedia Sp. z.o.o. in Polish Journal of Radiology
- Vol. 83, 63-67
Open AccessImaging in a rare case of neuroendocrine tumour with skin metastases
Purpose : Disseminated malignancies are a diagnostic and therapeutic challenge that is often encountered in radiology. Finding the primary tumour is crucial for planning proper surgical and oncological treatment. Computed tomography (CT) of the thorax and abdomen is typically the initial...
- Open Access
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 35 (4) , 425-428
Unilateral generalized morphea: a case report and literature review
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 35 (4) , 425-428
Open AccessUnilateral generalized morphea: a case report and literature review
- Open Access
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 35 (3) , 317-319
Folliculitis decalvans and orofacial granulomatosis
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 35 (3) , 317-319
Open AccessFolliculitis decalvans and orofacial granulomatosis
- Open Access
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 35 (2) , 227-229
Plane warts on the back of the hand successfully treated with oral isotretinoin
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 35 (2) , 227-229
Open AccessPlane warts on the back of the hand successfully treated with oral isotretinoin
- Open Access
- 12 October 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0186013
Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study
Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI). In a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry. During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0–6): 2491 [344–5587] vs. 3991 [1406–9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0–6): 473 [0–924] vs. 712 [346–1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0–12.0] vs. 2.5 [2.0–6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment. Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI. ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015)
- 12 October 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0186013
Open AccessComparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study
Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI). In a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry. During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0–6): 2491 [344–5587] vs. 3991 [1406–9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0–6): 473 [0–924] vs. 712 [346–1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0–12.0] vs. 2.5 [2.0–6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment. Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI. ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015)
- 1 May 2017
- Published by JLE in European Journal Of Dermatology
- Vol. 27 (3) , 227-236
Properties of skin stem cells and their potential clinical applications in modern dermatology
Stem cells play an important role in medical science, and scientists are investing large sums in order to perform sophisticated studies designed to establish potential clinical applications of stem cells. Growing experience has enabled researchers to determine the precise nature of stem cell division. Although the properties of this particular population of cells have been known and used for some time, mainly with regards to bone marrow-derived mesenchymal stem cell transplantation, we now face a significant challenge in implementing the practical use of skin-derived precursors, making it possible to avoid the necessity for patients to undergo invasive procedures in order to obtain stem cells from bone marrow. Multiple trials have so far been performed, bringing hope for the treatment of disorders previously considered untreatable. Patients suffering from a number of dermatological diseases, including malignant melanoma, systemic lupus erythematosus, vitiligo, alopecia or junctional epidermolysis bullosa, may benefit from treatment based on stem cells. The aim of this review is to summarize available data on stem cells and their potential applications in the treatment of dermatological disorders. The work described is based on data published up to the end of September 2016.
- 1 May 2017
- Published by JLE in European Journal Of Dermatology
- Vol. 27 (3) , 227-236
Properties of skin stem cells and their potential clinical applications in modern dermatology
Stem cells play an important role in medical science, and scientists are investing large sums in order to perform sophisticated studies designed to establish potential clinical applications of stem cells. Growing experience has enabled researchers to determine the precise nature of stem cell division. Although the properties of this particular population of cells have been known and used for some time, mainly with regards to bone marrow-derived mesenchymal stem cell transplantation, we now face a significant challenge in implementing the practical use of skin-derived precursors, making it possible to avoid the necessity for patients to undergo invasive procedures in order to obtain stem cells from bone marrow. Multiple trials have so far been performed, bringing hope for the treatment of disorders previously considered untreatable. Patients suffering from a number of dermatological diseases, including malignant melanoma, systemic lupus erythematosus, vitiligo, alopecia or junctional epidermolysis bullosa, may benefit from treatment based on stem cells. The aim of this review is to summarize available data on stem cells and their potential applications in the treatment of dermatological disorders. The work described is based on data published up to the end of September 2016.
- Open Access
- 1 January 2017
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 4 (4) , 363-365
Sweet’s syndrome with idiopathic epididymitis
- 1 January 2017
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 4 (4) , 363-365
Open AccessSweet’s syndrome with idiopathic epididymitis
- Open Access
- 1 January 2017
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 34 (6) , 622-624
Skin dissemination of myeloma
- 1 January 2017
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 34 (6) , 622-624
Open AccessSkin dissemination of myeloma